Fax: (507) 266-9277
Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy†
Version of Record online: 12 JUN 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 2, pages 433–438, 15 July 2006
How to Cite
Justice, T. E., Martenson, J. A., Wiseman, G. A. and Witzig, T. E. (2006), Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer, 107: 433–438. doi: 10.1002/cncr.21998
Presented at the 45th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City, UT, October 2003.
- Issue online: 5 JUL 2006
- Version of Record online: 12 JUN 2006
- Manuscript Accepted: 7 MAR 2006
- Manuscript Received: 5 JUL 2005
- National Cancer Institute. Grant Number: CA97274
- tumor response
Non-Hodgkin lymphomas (NHL) are radiosensitive tumors. Recent trials have demonstrated the effectiveness of beta irradiation delivered by monoclonal antibodies conjugated to radioisotopes such as yttrium-90 or iodine-131. Many patients eventually relapse after radioimmunotherapy (RIT) and require additional treatment. The goal of this study was to determine the safety and efficacy of external beam radiation therapy (EBRT) delivered after RIT.
We reviewed the records of 135 patients with relapsed B-cell NHL who had received RIT with 90Y-ibritumomab tiuxetan to identify patients who subsequently received EBRT. The response rates and radiation-induced toxicity from the EBRT were assessed.
Nineteen of 135 (14%) patients received EBRT to a total of 39 tumor sites. Complete radiation therapy records were available for 16 patients (36 tumor sites), which formed the basis for this analysis. The median EBRT dose was 28.5 Gy (range, 10–40 Gy), with a median fraction size of 2 Gy (range, 1–5 Gy). Response data were available for 29 treated sites. The overall response rate was 90% (26/29) with 12 complete responses (41%), 7 complete clinical responses (24%), 7 partial responses (24%), and 3 stable (10%). Toxicities were generally transient, reversible, and corresponded to the anatomic regions irradiated.
EBRT can produce tumor responses at sites of NHL that relapse after RIT with acceptable toxicity. Cancer 2006. © 2006 American Cancer Society.